Bioxytran's Medical Breakthrough in Fighting All Viruses
Bioxytran (OTCQB:BIXT) has announced a significant breakthrough in virology, validated in a peer-reviewed journal article. The company's drug candidate, Prolectin-M, has shown effectiveness in stopping COVID-19 and other viruses by blocking galectin, a protein important for viral attachment to cells. This discovery, made using advanced Nuclear Magnetic Resonance (NMR) spectroscopy, could impact both the antiviral and vaccination markets, collectively valued at approximately $147 billion.
The study revealed that galectins, located on the virus's spike protein, are an excellent drug target due to their stability. This could lead to the development of broad-spectrum antivirals effective against various viruses. Bioxytran's CEO, Dr. David Platt, believes this discovery represents a new era in antiviral drug development, potentially revolutionizing the treatment of viral diseases and even chronic illnesses like cancer.
Bioxytran (OTCQB:BIXT) ha annunciato una scoperta significativa in virologia, convalidata in un articolo di rivista peer-reviewed. Il candidato farmaco dell'azienda, Prolectin-M, ha dimostrato efficacia nel fermare il COVID-19 e altri virus bloccando la galectina, una proteina importante per l'attacco virale alle cellule. Questa scoperta, effettuata utilizzando avanzate spettroscopie di Risonanza Magnetica Nucleare (NMR), potrebbe avere un impatto sui mercati antivirali e delle vaccinazioni, valutati complessivamente a circa 147 miliardi di dollari.
Lo studio ha rivelato che le galectine, presenti nella proteina spike del virus, sono un eccellente target farmacologico grazie alla loro stabilità. Questo potrebbe portare allo sviluppo di antivirali ad ampio spettro efficaci contro vari virus. Il CEO di Bioxytran, Dr. David Platt, crede che questa scoperta rappresenti una nuova era nello sviluppo di farmaci antivirali,potenzialmente rivoluzionando il trattamento delle malattie virali e persino delle malattie croniche come il cancro.
Bioxytran (OTCQB:BIXT) ha anunciado un avance significativo en virología, validado en un artículo de revista revisado por pares. El candidato a fármaco de la empresa, Prolectin-M, ha demostrado eficacia para detener el COVID-19 y otros virus bloqueando la galectina, una proteína importante para la adhesión viral a las células. Este descubrimiento, realizado utilizando espectroscopia de Resonancia Magnética Nuclear (NMR) avanzada, podría impactar tanto en los mercados de antivirales como de vacunaciones, valorados en aproximadamente 147 mil millones de dólares.
El estudio reveló que las galectinas, ubicadas en la proteína espiga del virus, son un excelente objetivo farmacológico debido a su estabilidad. Esto podría llevar al desarrollo de antivirales de amplio espectro efectivos contra varios virus. El CEO de Bioxytran, Dr. David Platt, cree que este descubrimiento representa una nueva era en el desarrollo de fármacos antivirales, potencialmente revolucionando el tratamiento de enfermedades virales e incluso enfermedades crónicas como el cáncer.
바이옥시트란(Bioxytran, OTCQB:BIXT)은 동료 검토 저널 기사에서 검증된 바이러스학의 중요한 돌파구를 발표했습니다. 회사의 약물 후보인 프로렉틴-M은 COVID-19 및 기타 바이러스를 차단하는 데 효과가 있음을 보여주었으며, 이는 세포에 대한 바이러스 부착에 중요한 단백질인 겔레틴을 차단합니다. 이 발견은 고급 핵 자기 공명(NMR) 분광학을 사용하여 이루어졌으며, 항바이러스제 및 백신 시장에 각각 약 1,470억 달러로 평가되는 영향을 미칠 수 있습니다.
연구에 따르면 바이러스의 스파이크 단백질에 위치한 겔레틴은 안정성 덕분에 훌륭한 약물 표적입니다. 이것은 다양한 바이러스에 효과적인 광범위 항바이러스제 개발로 이어질 수 있습니다. 바이옥시트란의 CEO인 데이비드 플랫 박사는 이 발견이 항바이러스 약물 개발의 새로운 시대를 나타내며, 바이러스 질병 치료 및 심지어 암과 같은 만성 질환 치료를 혁신할 가능성이 있다고 믿고 있습니다.
Bioxytran (OTCQB:BIXT) a annoncé une avancée significative en virologie, validée dans un article d'un journal évalué par des pairs. Le candidat médicament de l'entreprise, Prolectin-M, a montré son efficacité à stopper le COVID-19 et d'autres virus en bloquant la galectine, une protéine importante pour la liaison virale aux cellules. Cette découverte, réalisée grâce à des spectroscopes par résonance magnétique nucléaire (NMR) avancés, pourrait avoir un impact sur les marchés de l'antiviral et de la vaccination, d'une valeur totale d'environ 147 milliards de dollars.
Cette étude a révélé que les galectines, situées sur la protéine spike du virus, constituent une excellente cible médicamenteuse en raison de leur stabilité. Cela pourrait conduire au développement d'antiviraux à large spectre efficaces contre divers virus. Le PDG de Bioxytran, Dr. David Platt, estime que cette découverte représente une nouvelle ère dans le développement de médicaments antiviraux, révolutionnant potentiellement le traitement des maladies virales et même des maladies chroniques comme le cancer.
Bioxytran (OTCQB:BIXT) hat einen bedeutenden Durchbruch in der Virologie angekündigt, der in einem von Experten begutachteten Fachartikel bestätigt wurde. Der Medikamentenkandidat des Unternehmens, Prolectin-M, hat sich als wirksam erwiesen, um COVID-19 und andere Viren zu stoppen, indem er Galektin blockiert, ein Protein, das für die virale Bindung an Zellen wichtig ist. Diese Entdeckung, die mithilfe fortschrittlicher kernmagnetischer Resonanzspektroskopie (NMR) gemacht wurde, könnte sowohl die Antiviren- als auch die Impfstoffmärkte beeinflussen, die zusammen auf etwa 147 Milliarden US-Dollar geschätzt werden.
Die Studie ergab, dass Galektine, die auf dem Spike-Protein des Virus lokalisiert sind, ein hervorragendes Ziel für Medikamente aufgrund ihrer Stabilität darstellen. Dies könnte zur Entwicklung von broad-spectrum Antivirenmitteln führen, die gegen verschiedene Viren wirksam sind. Der CEO von Bioxytran, Dr. David Platt, glaubt, dass diese Entdeckung eine neue Ära in der Entwicklung antiviraler Medikamente darstellt, die das Potenzial hat, die Behandlung von viralen Erkrankungen und sogar chronischen Krankheiten wie Krebs zu revolutionieren.
- Prolectin-M shown to be 100% effective in reducing symptoms and eliminating COVID-19 virus in two peer-reviewed clinical trials
- Discovery of galectin-blocking mechanism could lead to broad-spectrum antivirals effective against multiple virus families
- Advanced NMR spectroscopy used for precise analysis, improving upon 50-year-old ELISA tests
- Potential to rapidly develop new antiviral drugs against emerging viral threats
- Targeting galectins could provide a more reliable antiviral approach independent of individual immune system variations
- No specific financial data or revenue projections provided for Bioxytran's potential market impact
- Clinical trials to COVID-19, efficacy against other viruses not yet proven
- Potential challenges in navigating regulatory approvals for a novel antiviral approach not addressed
Breakthrough was validated in the latest journal article
Galectins are essential for viral entry and a new target for drug development
Carbohydrates were shown to neutralize viruses
Blocking galectins could be the most efficient way to prevent and treat viruses potentially impacting the vaccination and antiviral markets
BOSTON, MA / ACCESSWIRE / September 19, 2024 / BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced a medical breakthrough in virology that was validated in a peer-reviewed medical journal article. The European Society of Medicine published a peer-reviewed article detailing a study which shows how Bioxytran's leading drug candidate, Prolectin-M, stops COVID-19 and other viruses in their tracks. The study used advanced Nuclear Magnetic Resonance (NMR) spectroscopy to reveal how this drug works by blocking a protein called galectin, which helps viruses attach to cells. The discovery could impact both the vaccination and antiviral markets, which combined are estimated at approximately
https://esmed.org/MRA/mra/article/view/5616
The peer-reviewed article identified Galectin-3 as a crucial "glue" that helps the virus attach to and enter human cells by sticking to the ACE2 receptor, altering our existing understanding of how viral infections occur. The discovery was proven using NMR Spectroscopy which is extremely precise compared to the 50-year-old ELISA tests which was used to establish virology's initial foundation on how viruses worked and interacted with antivirals. The report proved that by blocking this process, the drugs prevented the virus from entering the cells, which means the virus couldn't make people sick. The double-blind placebo controlled clinical studies showed that these drugs were
The study also pointed out that galectins, located on the spike protein of the virus, are an excellent target for drugs because it doesn't change much, making it easier to stop the virus from attaching to cells. This could make these drugs effective against a wide range of viruses, not just COVID-19.
"This discovery might be one of the most significant advancements in virology," said Dr. David Platt, CEO of Bioxytran. "In our first case study to make a SARS-CoV-2 antiviral drug, it appears we have on our hands the first truly broad-spectrum antiviral that may operate across different families of viruses. We believe we have discovered a reproducible method that could potentially be used to create many antiviral drugs that could potentially quickly fight off new viruses, even those that mutate rapidly. We believe our approach represents a new era in antiviral drug development. With the help of advanced technology and Artificial Intelligence (AI), it is now possible to design antiviral drugs that could potentially neutralize any virus. This discovery could change the way we treat viral diseases and even chronic illnesses like cancer. We believe major advancements in virology with this new tech will be measured in months instead of years and decades as has been the case in the past."
"Using this new platform technology could revolutionize how we create new antiviral treatments," said Dr. Kevin Mayo, Professor of the University of Minnesota. "Traditional methods of developing antivirals and vaccines are not precise and involve a lot of trial and error. Their weakness has always been their reliance on the immune system to work properly and everyone's immune system is unique. Our results show we can neutralize viruses without the help of the immunes system making our system incredibly reliable. This breakthrough opens a new chapter in fighting viral diseases, providing hope for treating not only SARS-CoV-2 but other highly pathogenic and contagious viruses influenced by galectins. This may be the crown jewel of virology and a few more tests on other viruses could prove it."
Antiviral and Vaccination Market
The global antiviral drugs market is valued at
The COVID-19 pandemic accelerated vaccine development and distribution. New technological advancements in mRNA technology, protein-based vaccines, and microarray patches are enhancing efficacy, stability and accessibility of vaccines. Growing indications include HPV, pneumococcal infections, and RSV. Global health initiatives to combat malaria and tuberculosis are also driving the development of new vaccines.
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company pioneering a library of novel complex carbohydrate structures using artificial intelligence software that interprets the Nuclear Magnetic Resonance imaging of druggable targets like the galectin fold to create a rational drug design. The leading drug candidates vetted by in vitro testing, are capable of neutralizing viruses. The peer-reviewed discovery of the galectin fold located on the spike proteins of viruses such as COVID-19, RSV, and H1N1 demonstrate there exists a conserved region on the spike in which Bioxytran's molecules achieve virus neutralization. The extent of the carbohydrate structure's ability to neutralize untested viruses is unknown just like the initial discovery of antibiotics last century and its ability to treat a broad spectrum of bacterial infections. Applications of this platform technology extend to the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
SOURCE: BioXyTran, Inc.
View the original press release on accesswire.com
FAQ
What is Bioxytran's (BIXT) breakthrough in fighting viruses?
How does Bioxytran's (BIXT) Prolectin-M work against viruses?
What technology did Bioxytran (BIXT) use to validate their antiviral discovery?
What potential market impact could Bioxytran's (BIXT) antiviral breakthrough have?
